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To The Editor
Pasipanodya and Gumbo compared self-administered therapy (SAT) with directly observed 
therapy (DOT) to determine the proportion of cases with microbiologic failure, relapse, and 
acquired drug resistance among a pooled cohort of 12 482 persons with tuberculosis from 10 
independent studies [1]. The concept of DOT first emerged as a potential therapeutic 
alternative to resource-intensive hospitalization [2]. Shortly after the introduction of oral 
antibiotics and during a time when the prevalence of tuberculosis exceeded the availability 
of hospital beds, well-organized, provider-supervised ambulatory care became the only 
viable option [2, 3]. However, it was unclear if such therapy could achieve the same success 
rate as long-term hospitalization. Randomized trials from the late 1950s demonstrated 
similar patient outcomes to those of hospitalization [3, 4], and thus resources began to shift 
away from sanatorium-era approaches to clinic-based approaches that have since evolved 
into the accepted standard of practice for tuberculosis management with DOT. Today similar 
resource restrictions have forced tuberculosis programs to rethink this strategy and consider 
less resource-intensive alternative approaches. The polarizing debate and controversy about 
DOT efficacy is not new [5, 6] and Pasipanodya and Gumbo are not the first to use meta-
analysis to seek evidence for consensus [7, 8].
Unfortunately, this analytic approach suffers from some potential methodological problems. 
First, the strength and validity of any meta-analysis is determined by criteria used to select 
the available pooled cohort. There are practical impediments to conducting well-designed 
studies on DOT efficacy. The chief among these is an ethical issue. An essential component 
of human research protection in clinical trials is the participant’s ability to withdraw from a 
study at any time with no loss of privileges or rights. Unlike other illnesses evaluated by 
randomized trials, tuberculosis is a public health problem that affects others in the 
community through respiratory transmission. As a result, physicians and laboratories in 
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many areas are legally required to report the identity of persons with tuberculosis to health 
authorities. To prevent tuberculosis transmission, persons with tuberculosis who are 
noncompliant with treatment can face loss of personal liberty. Randomization to a study 
treatment that, if not followed, can result in loss of liberty and legally mandated treatment or 
isolation by public health authorities is problematic. Moreover, the studies with a 
randomized design that did meet the authors’ selection criteria included patients who had to 
make heroic efforts to receive DOT by reporting to a clinic during working hours. There was 
no support or incentives for transportation, nor financial provisions made for the income loss 
due to missed work. This type of DOT may result in work absence and income loss, thus 
potentially creating financial hardship for any enrolled patient, especially in developing 
countries. Second, 6 of 10 studies used sputum smear microscopy for diagnosis and clinical 
follow-up and were not tested for drug-resistant tuberculosis by culture prior to 
randomization [9–14]. Therefore, persons with drug-resistant tuberculosis had an equal 
chance of assignment in each arm. As such, it would follow that poor treatment outcomes 
associated with drug-resistant tuberculosis (ie, increased acquired drug resistance, failure, 
relapse, and death) would bias the comparison to the null. Third, 3 of 10 studies included 
both new and retreatment cases prior to randomization [15–17]. In a similar way to drug-
resistant tuberculosis, persons with previous tuberculosis treatment are at higher risk of poor 
outcome, including increased acquired drug resistance, default, failure, relapse, and death. 
Fourth, for 3 of 10 studies there was a strong potential for bias induction; that is, persons 
with known risk factors for noncompliance were selected nonrandomly to the DOT arm, and 
conversely persons without known risk factors were selected nonrandomly to the SAT arm 
or crossed over treatment arms during the study, thus biasing the potential outcomes to the 
null [12, 14, 16].
Due to these ethical and methodological issues, we do not agree that these data support 
“shifting away resources” from DOT. Moreover, we contend that the societal savings of 
preventing secondary transmission and acquired drug-resistant tuberculosis, when properly 
managed through community-based DOT, are greater than the programmatic cost of DOT 
delivery. Although SAT may be less resource intensive, it is not equal to the cost-benefit 
potential of DOT-based programs—buyer beware.
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